A 50-year-old with a new diagnosis of type 2 diabetes (A1C 9.1%) and obesity (BMI 37 kg/m²) without ASCVD or CKD asks about weight-centric pharmacothe...

Question

A 50-year-old with a new diagnosis of type 2 diabetes (A1C 9.1%) and obesity (BMI 37 kg/m²) without ASCVD or CKD asks about weight-centric pharmacotherapy. Which is preferred?

Accepted Answer

GLP-1 receptor agonist with weight loss efficacy

Answer

DPP-4 inhibitor

Answer

Sulfonylurea

Answer

Thiazolidinedione

Answer

Basal insulin as first-line

us-abim MCQ (SBA): Type 2 Diabetes (Weight-Centric Rx)

A 50-year-old with a new diagnosis of type 2 diabetes (A1C 9.1%) and obesity (BMI 37 kg/m²) without ASCVD or CKD asks about weight-centric pharmacotherapy. Which is preferred?